|
Mar 26
|
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
|
|
Mar 21
|
ARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial Results
|
|
Mar 21
|
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 15
|
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
|
|
Mar 7
|
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
|
|
Mar 6
|
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
|
|
Feb 26
|
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
|
|
Oct 3
|
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
|
|
Oct 3
|
Chief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Inc
|
|
Sep 29
|
ARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investors
|
|
Sep 29
|
3 Small Biotech Stocks That Could Be Stars
|
|
Aug 10
|
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
|